Nan Fung Life Sci­ences antes up $32M to fu­el a neu­ro play as the Hong Kong con­glom­er­ate burns through $1.5B man­date

Hav­ing re­lied heav­i­ly on its Piv­otal bioVen­tures Part­ners arm to make di­rect in­vest­ments in biotech, Nan Fung Life Sci­ences is tak­ing an in­creas­ing­ly promi­nent seat at the ta­ble, putting up $32 mil­lion as the sole in­vestor in a neu­ro­science start­up’s launch round.

With the Se­ries A En­grail Ther­a­peu­tics is al­so tak­ing the cov­ers off its busi­ness mod­el, which in­volves find­ing, buy­ing and then de­vel­op­ing drugs for brain dis­or­ders.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER